FDA Approves Infilbray (venglustat) to Treat Neurological Manifestations of Type 3 Gaucher Disease

Nov 19, 2026 - 04:00
 0  0
Paris, November 18, 2026. The US Food and Drug Administration has approved Infilbray (venglustat), a novel, oral glucosylceramide synthase inhibitor (GCSi) that acts across the blood-brain barrier, for the treatment of neurological manifestations...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0